TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: area under the plasma concentration versus time curve (AUC(tau)) of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration of bosentan (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration versus time curve (AUC(tau)) of bosentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HAMD-17 score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BDI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FA scores improvement in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proton pump inhibitor prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of having potentially inappropriate prescriptions (PIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary SIgA secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: gain in knowledge on mental health care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Basal levels of IL-1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Basal levels of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Basal levels of TNFalpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: control of postoperative IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: bioequivalence of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: areas under the plasma concentration–time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function (FEV1/FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urine leakage cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: immediate verbal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: verbal fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine albumin-to-creatinine ratio reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Remission rates of albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: family communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: conversations about cancer
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Prevalence of degenerative spondylolisthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of lumbar disc degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of lumbosacral transitional segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PTX3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driving simulator performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: volume of homologous transfusion required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Impairment of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reported fullness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HPV DNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: REE/kg level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ln-HOMA-IR score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-reaction protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal neoplasia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Advanced neoplasia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of chronic lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: enamel remineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake rate of appointments at the WCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative appendectomy rate
Endpoint domain: Adverse events/effects
Primary endpoint: classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of severe mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity for the diagnosis of malignant ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite rate of cardiac death or MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 1-year target lesion revascularization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Net clinical benefit of LAA closure
Endpoint domain: Mortality/survival
Primary endpoint: Electrical pain tolerance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain outcomes
Primary endpoint: Mean bond strength values (MPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: doubling dose improvement in methacholine PD20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: quality of life (symptoms and emotions)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MIDUS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nocturnal fall of diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AOFAS hindfoot clinical outcome scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: molecular relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of Major Depressive Disorder (MDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Internalizing symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Externalizing symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Corticosteroid-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infected necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peroneus longus latency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: muscle sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Flow-mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IgE-binding potency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hypo-allergenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median Survival (MS)
Endpoint domain: Mortality/survival
Primary endpoint: Risk of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of prediabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse long-term outcomes in infants
Endpoint domain: Adverse events/effects
Primary endpoint: Growth below the 3rd percentile in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Reduced number of required lateral releases
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Coronary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of PID
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in BDNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Availability of renal replacement therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time from indication to onset of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total work done
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorylation of AMPK(Thr172)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA expression of PGC-1α, VEGF, and HIF-1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in skin itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in hepatic fibrosis indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvement in respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in PFT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in use of inhaler and oral medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Trial participation acceptance
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: productivity
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: calmness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: contentedness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RANKL/OPG ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NEI VFQ-25 composite score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DP-6 composite score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Moderate or severe apical thinning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum free DNA hTERT content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein content of TERT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conduction block detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Seroprotection rates one month post-dose-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: patient-rated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of NEC (Bell stage >/=II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of perforation (Bell stage III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to full enteral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of full enteral feeding days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported absenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from baseline in AISRS at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall mean satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction with outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of shallow anterior chambers
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of pooled testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolo scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ghrelin level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of potential respiratory pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma phenytoin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of surgical field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anaesthetic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lung cancer probability
Endpoint domain: Mortality/survival
Primary endpoint: Phacoemulsification time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: health and functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activated Clotting Times (ACTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative left atrium dimensions (LADs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection rates of C. trachomatis
Endpoint domain: Adverse events/effects
Primary endpoint: Successful placement of feeding tubes on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to initiation of feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective vaccine efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: safety and efficacy of B‐TURP and M‐TURP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free hours of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral suppression (plasma HIV‐1 RNA level < 500 copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent decrease in contraction frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytogenetic response failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of death
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of HFE/death
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of VTA/death
Endpoint domain: Mortality/survival
Primary endpoint: CVL on the plateaus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BML score in the medial compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: neonatal facial score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cry duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in parasympathetic tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of CbpA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: New AIDS event or death
Endpoint domain: Mortality/survival
Primary endpoint: Normalization of plasma total homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6MWD response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS positive score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enduring remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of use of the affected arm-hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of use of the affected arm-hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in HbA(1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Enhanced motivation to improve blood glucose management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of colonization by penicillin-susceptible organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: plasma iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with clear ACC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Amplitude of P40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of P40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good decision quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wait time reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ulcer size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain level variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee extensors peak isokinetic power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tendon stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: postural balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adult chronic pain complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak cortisol response to naloxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the cortisol time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GSV occlusion rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNFL thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average sum score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antirabies antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects experiencing local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects experiencing systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Time from randomization to simultaneous RRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endogenous glucose production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose disposal and oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Wingate power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cesarean section rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: operative delivery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: neonatal morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Patency of the infarct vessel before PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes